CD274 and neoplasm: This study, by integrating MHC-II scoring from the I-SPY2 immunotherapy cohort, performed a cross-sectional comparison with TILs, PD-L1, TLS, and T-cell pathways, revealing that tsMHC-II exhibits the highest predictive efficacy for immunotherapy benefit.The NeoTRIP spatial proteomics study confirmed that MHC-I+MHC-II+ tumor cell expression is the most relevant predictor of pCR in anthracycline-free PCb regimens [34].